Is Adaptive Biotechnologies (ADPT) Cheap After Its 16% Pullback?

Adaptive Biotechnologies (ADPT) has drawn investor attention after a recent pullback, with the share price down about 16% over the past month even as year to date performance remains strongly positive.

Recent trading has cooled some of that enthusiasm, with a 1-day share price return of down 6.1%, a 7-day move of down 6.1% and a 30-day share price return of down 16%, even though the 90-day share price return is up 6.4% and the year to date share price return is up 51%. The latest share price of $24.02 sits against a 1-year total shareholder return of 34.7%, while the 3-year total shareholder return is roughly 5x. This suggests that recent weakness may reflect a shift in risk perception more than a change in the long term story for Adaptive Biotechnologies.

Scan beyond Adaptive Biotechnologies and explore other high-potential healthcare and biotech names using our hand picked list of 33 healthcare AI stocks

The question now is whether Adaptive Biotechnologies’ sharp pullback reflects something changing in the business itself or mostly a reset in sentiment around a stock that has already delivered strong multiyear gains. That is where valuation comes in.

Most Popular Narrative: 15% Undervalued

Against the last close at $24.02, the most widely followed fair value estimate of $28.31 implies Adaptive Biotechnologies trades at a meaningful discount, and the narrative around that gap leans heavily on the strength of its MRD franchise and improving profitability profile.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

See why 8 investors see Adaptive Biotechnologies as 15% undervalued.

Result: Fair Value of $28.31 (UNDERVALUED)

Still, the story around Adaptive Biotechnologies can change quickly if reimbursement for clonoSEQ becomes less predictable or if ongoing company wide losses start to pressure the balance sheet.

Find out about the key risks to this Adaptive Biotechnologies narrative.

Another View: What The Sales Multiple Says About Adaptive Biotechnologies

The story shifts when you look at Adaptive Biotechnologies through its P/S ratio. The stock trades at 12.4x sales compared with 4.5x for the wider US Life Sciences group and a fair ratio estimate of 5x. That gap points to meaningful valuation risk if sentiment cools. Is the MRD growth story strong enough to justify such a premium?

For a closer look at how this pricing compares with underlying fundamentals, review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Adaptive Biotechnologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 33 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Adaptive Biotechnologies looks mixed, with clear risks on one side and meaningful potential on the other. Move quickly, review the underlying data, and weigh both the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Adaptive Biotechnologies?

If you stop with Adaptive Biotechnologies, you risk missing other opportunities. Use objective screeners to quickly surface candidates that fit the portfolio you actually want.

• Target potential mispricings by scanning a focused list of companies that combine quality fundamentals with attractive valuations through the 33 high quality undervalued stocks.
• Strengthen portfolio resilience by filtering for businesses that carry manageable debt and healthy cash positions using the list of solid balance sheet and fundamentals (25 results).
• Spot lesser known prospects with robust metrics before they hit everyone’s radar by running the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com